Search

Displaying results 1241 - 1250 of 5897 in total
  1. Drug

    mRNA-1010

    go.drugbank.com/drugs/DB22484
    Approved

    benefit to be confirmed in a postmarketing trial. … [L64058] Each dose contains three mRNAs encapsulated in lipid nanoparticles, each encoding the hemagglutinin (HA) glycoprotein of one influenza strain recommended for the season; after intramuscular injection

  2. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    [A218186, L32118] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit drastically reduced metabolic degradation compared to traditional synthetic oligonucleotides. … [A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen].

  3. Drug

    Asparagine

    go.drugbank.com/drugs/DB00174
    ApprovedNutraceuticalWithdrawn

    A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. (From Concise Encyclopedia Biochemistry and M...

    Mixtures: The Classeum Co., Ltd., The Classeum Co., Ltd.
  4. Drug

    5-deoxyflavanone

    go.drugbank.com/drugs/DB03601
    Experimental

    This compound belongs to the flavanones. … These are compounds containing a flavan-3-one moiety, whose structure is characterized by a 2-phenyl-3,4-dihydro-2H-1-benzopyran bearing a ketone at the carbon C3.

  5. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    [L64117,L64107,L64116] It is the first next-generation oral SERD and complete ER antagonist approved in the first-line setting, and the only one approved for use with all three widely approved CDK4/6 inhibitors … Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally

  6. Drug

    Satraplatin

    go.drugbank.com/drugs/DB04996
    Investigational

    Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy.

  7. Drug

    Fenofibrate

    go.drugbank.com/drugs/DB01039
    ApprovedInvestigational

    [A185954] Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.[L8585]

    Products: FENOFIBRATO DOC GENERICI
  8. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard … Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease

  9. Drug

    Treprostinil

    go.drugbank.com/drugs/DB00374
    ApprovedInvestigational

    However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature. … The first generic form of treprostinil became available in 2019.[A248775]

  10. Drug

    Isosorbide mononitrate

    go.drugbank.com/drugs/DB01020
    ApprovedInvestigational

    [L11743] Isosorbide mononitrate has a longer duration of action than [nitroglycerin] due to its slow onset of absorption and metabolism. … It is an anti-anginal agent that works by relaxing the smooth muscles of both arteries and veins, but but predominantly veins to reduce cardiac preload.

    Products: ISOSORBIDE MONONITRATO DOC GENERICI, ISOSORBIDE MONONITRATO SIGMA TAU GENERICS